Table 1 Summary of the viral load data used for modeling
From: Designing isolation guidelines for COVID-19 patients with rapid antigen tests
Country | Number of data | Reporting unit | Specimens for measuring viral load | Date of collection | Source |
|---|---|---|---|---|---|
Symptomatic | |||||
USA | \(33\) | viral load (copies/mL) | Nares and oropharyngeal swabs | Nov 2020 to May 2021 | ref. 44 |
USA | \(12\) | viral load (copies/mL) | Nares and oropharyngeal swabs | Nov 2020 to May 2021 | ref. 26 |
Germany | \(8\) | viral load (copies/swab)b | Pharyngeal swab | Jan 2020 | ref. 19 |
Korea | \(34\) | cycle thresholda | Oro/nasopharyngeal swabs | May 2020 | ref. 45 |
Korea | \(2\) | cycle thresholda | Oro/nasopharyngeal swab | Feb 2020 | ref. 46 |
Singapore | \(12\) | cycle thresholda | Nasopharyngeal swab | Jan to Feb 2020 | ref. 47 |
China | \(8\) | cycle thresholda | Nasal swab | Jan 2020 | ref. 48 |
Asymptomatic | |||||
USA | \(44\) | viral load (copies/mL) | Nares and oropharyngeal swabs | Nov 2020 to May 2021 | ref. 44 |
USA | \(28\) | viral load (copies/mL) | Nares and oropharyngeal swab | Nov 2020 to May 2021 | ref. 26 |
Japan | \(18\) | cycle thresholda | Nasopharyngeal or throat swab | Jan 2020 | ref. 49 |
Korea | \(4\) | cycle thresholda | Nasal and throat swabs | Feb to Apr 2020 | ref. 50 |
Singapore | \(7\) | cycle thresholda | Nasopharyngeal swab | Mar to Apr 2020 | ref. 51 |
